Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 161

Results For "MIT"

5110 News Found

Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25
News | September 04, 2024

Cupid targets Rs. 50 crore+ topline from B2C in FY 2024-25

Innovative product offerings to capitalise on emerging opportunities within and beyond the sexual wellness market


Siegfried opens quality control lab in Minden
News | September 04, 2024

Siegfried opens quality control lab in Minden

The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant


NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
News | September 04, 2024

NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis

eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage


Lupin launches Mirabegron ER tablets in US
Drug Approval | September 04, 2024

Lupin launches Mirabegron ER tablets in US

Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development


Lupin launches Doxorubicin Hydrochloride Liposome Injection in US
Drug Approval | September 03, 2024

Lupin launches Doxorubicin Hydrochloride Liposome Injection in US

ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA


Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure
Clinical Trials | September 02, 2024

Finerenone showed statistically significant improvement in cardiovascular outcomes in adults with common form of heart failure

Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%


Biocon Pharma receives USFDA approval for daptomycin
Drug Approval | September 01, 2024

Biocon Pharma receives USFDA approval for daptomycin

The approval further adds to Biocon’s portfolio of complex drug products


Thyrocare to acquire diagnostic and pathological services business of Vimta Labs
News | August 31, 2024

Thyrocare to acquire diagnostic and pathological services business of Vimta Labs

Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025